Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

Rhea-AI Summary

Ocugen (NASDAQ: OCGN) will host a conference call and live webcast on Thursday, January 15, 2026 at 8:30 a.m. ET to discuss data from the first half of patients reaching one year after treatment in the OCU410 Phase 2 ArMaDa clinical trial. The event will feature KOLs and Ocugen executive leadership, including Dr. Arshad M. Khanani, Dr. Jay Chhablani, and Dr. Lejla Vajzovic.

Dial-in numbers: (800) 715-9871 (U.S.) and (646) 307-1963 (international); Conference ID: 7783588. A webcast and replay will be available on the company’s investor site events section.

News Market Reaction

+7.30%

13 alerts

+7.30% News Effect

+3.2% Peak Tracked

-12.2% Trough Tracked

+$38M Valuation Impact

$556M Market Cap

1.0x Rel. Volume

On the day this news was published, OCGN gained 7.30%, reflecting a notable positive market reaction. Argus tracked a peak move of +3.2% during that session. Argus tracked a trough of -12.2% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $38M to the company's valuation, bringing the market cap to $556M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Webcast date: January 15, 2026 Webcast time: 8:30 a.m. ET Conference ID: 7783588 +2 more

5 metrics

Webcast date January 15, 2026 OCU410 Phase 2 ArMaDa data discussion

Webcast time 8:30 a.m. ET Start time for conference call and webcast

Conference ID 7783588 Dial-in access code for webcast

U.S. dial-in (800) 715-9871 Domestic access number for webcast

International dial-in (646) 307-1963 International access number for webcast

Market Reality Check

Price: $1.45 Vol: Volume 9,892,203 is 2.22x...

high vol

$1.45 Last Close

Volume Volume 9,892,203 is 2.22x the 20-day average (4,451,993), showing elevated interest ahead of the webcast. high

Technical Price $1.78 is trading above the $1.13 200-day MA, reflecting a pre-existing upward trend.

Peers on Argus

OCGN gained 18.67% with elevated volume, while peers were mixed: some modestly h...

OCGN gained 18.67% with elevated volume, while peers were mixed: some modestly higher (e.g., MBX +13.16%, FDMT +1.35%, BNTC +1.25%) and others lower (DSGN -2.04%, LRMR -2.99%), suggesting a stock-specific move.

Historical Context

5 past events · Latest: Jan 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 09	Conference presentation	Positive	+0.7%	CEO presentation at J.P. Morgan conference and BLA timeline commentary.
Dec 10	Conference appearance	Positive	+1.6%	Rare disease summit fireside chat and 2026 catalyst discussion.
Nov 20	Investor conference	Positive	-2.6%	NobleCon21 presentation on gene therapy strategy and BLA goals.
Nov 05	Earnings update	Negative	-1.4%	Q3 2025 results, financing, and ongoing clinical development update.
Oct 23	Earnings call setup	Neutral	+1.3%	Announcement of Nov 5 webcast to discuss Q3 results and business.

Pattern Detected

Recent news events, mostly conference and update-related, have generally led to modest price moves, with one notable negative divergence after a positive conference announcement.

Recent Company History

Over the last few months, Ocugen has focused on conference visibility and clinical platform messaging. Events on Nov 20, 2025, Dec 10, 2025, and Jan 9, 2026 highlighted CEO presentations and strategy discussions around multiple planned BLAs. Earnings and financing updates on Nov 5, 2025 emphasized cash position, clinical progress, and licensing economics. Today’s OCU410 Phase 2 data webcast fits into this pattern of incremental clinical and strategic disclosures for the gene-therapy portfolio.

Market Pulse Summary

The stock moved +7.3% in the session following this news. A strong positive reaction aligns with ant...

Analysis

The stock moved +7.3% in the session following this news. A strong positive reaction aligns with anticipation around the upcoming OCU410 Phase 2 ArMaDa data discussion. Shares traded above the $1.13 200-day MA with volume at 2.22x average, suggesting elevated speculative interest. Historically, clinical updates have produced mixed follow-through, so later data details and any subsequent financing or corporate actions could have influenced whether gains were sustained.

Key Terms

phase 2, clinical trial, webcast, kol

4 terms

phase 2 medical

"OCU410 Phase 2 ArMaDa clinical trial at 8:30 a.m. ET on Thursday"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

clinical trial medical

"patients completing one year since treatment in the OCU410 Phase 2 ArMaDa clinical trial"

A clinical trial is a carefully controlled study in which a new medicine, medical device, or treatment is tested on people to see if it is safe and effective. For investors it matters because trial results determine whether a product can win regulatory approval and reach patients, much like a road test decides if a new car can be sold; positive or negative results can sharply change a company’s prospects and stock value.

webcast technical

"conference call and live webcast with KOLs and Ocugen executive leadership"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

kol technical

"live webcast with KOLs and Ocugen executive leadership to discuss data"

A KOL, or key opinion leader, is a trusted expert—often a leading physician, researcher, or specialist—whose views influence peers, clinical practice, and industry adoption of medical products or treatments. For investors, KOL endorsements or criticisms can sway adoption rates, regulatory perceptions, and market confidence much like a respected critic can affect demand for a new product, so monitoring KOL sentiment helps gauge commercial and clinical prospects.

AI-generated analysis. Not financial advice.

MALVERN, Pa., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast with KOLs and Ocugen executive leadership to discuss data from the first half of patients completing one year since treatment in the OCU410 Phase 2 ArMaDa clinical trial at 8:30 a.m. ET on Thursday, January 15, 2026.

Study investigators leading the webcast include:

• Arshad M. Khanani, MD, MA, FASRS, Director of Clinical Research, and Director of Fellowship at Sierra Eye Associates and Clinical Professor at the University of Nevada, Reno School of Medicine
  
• Jay Chhablani, MD, Vitreo-Retina Specialist at the University of Pittsburgh Eye Center
  
• Lejla Vajzovic, MD, FASRS, Professor of Ophthalmology, Director of CME-Ophthalmology, Duke University School of Medicine
  

Attendees are invited to participate on the call using the following details:

Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callers
Conference ID: 7783588
Webcast: Available on the events section of the Ocugen investor site

A replay of the call and archived webcast will be available following the event on the Ocugen investor site.

About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:
Tiffany Hamilton
AVP, Head of Communications
Tiffany.Hamilton@ocugen.com

FAQ

When will Ocugen (OCGN) discuss OCU410 Phase 2 ArMaDa one-year data?

Ocugen will discuss the data on January 15, 2026 at 8:30 a.m. ET during a live webcast and conference call.

How can investors join the Ocugen (OCGN) webcast for the OCU410 Phase 2 update?

Join via the webcast on the company investor site events section or dial (800) 715-9871 (U.S.) or (646) 307-1963 (international) with Conference ID 7783588.

Who will present Ocugen's (OCGN) OCU410 Phase 2 ArMaDa one-year patient data on January 15?

Presenters include KOLs Dr. Arshad M. Khanani, Dr. Jay Chhablani, Dr. Lejla Vajzovic, and Ocugen executive leadership.

Will a replay of the Ocugen (OCGN) OCU410 webcast be available after the January 15 event?

Yes. A replay and archived webcast will be available following the event on the Ocugen investor site.

What specific OCU410 patient cohort will be discussed in the Ocugen (OCGN) webcast?

The webcast covers data from the first half of patients who have completed one year since treatment in the Phase 2 ArMaDa trial.